Long-term outcome study of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab

Long-term outcome study of patients with refractory nephrotic syndrome after multicenter, double blind, randomized, placebo-controlled trial of rituximab - Long-term outcome study of patients with nephrotic syndrome treated with rituximab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015220

Enrollment

Registered

2014-09-22

Start date

2014-09-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory nephrotic syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory nephrotic syndrome who was enrolled in the multicenter, double blind, randomized, placebo-controlled trial of rituximab

Exclusion criteria

Exclusion criteria: Patients who did not participate in the trial

Design outcomes

Primary

Measure	Time frame
First relapse after rituximab treatment	—

Secondary

Measure	Time frame
1. Administration of immunosuppressive agents after rituximab treatment 2. Re-treatment of rituximab 3. Late onset adverse events after rituximab treatment	—

Countries

Japan

Contacts

Public ContactKoichi Kamei

National Center for Child Health and Development Nephrology and Rheumatology

kamei-k@ncchd.go.jp03-5494-7128

Outcome results